Related Experiment Videos
Immunointervention in primary biliary cirrhosis: an overview.
1Institute of Liver Studies, King's College Hospital School of Medicine and Dentistry, Denmark Hill, London, UK.
Journal of Autoimmunity
|April 1, 1992
Summary
Cyclosporin A treatment in primary biliary cirrhosis (PBC) may delay death or transplantation. This immunomodulatory drug showed a reduction in liver-related deaths and slowed bilirubin rise with low toxicity.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Autoimmune processes are implicated in the early stages of primary biliary cirrhosis (PBC).
- Immunomodulatory drugs are explored to improve outcomes in PBC patients.
- Previous agents like corticosteroids and azathioprine have been investigated.
Purpose of the Study:
- To evaluate the efficacy and safety of cyclosporin A in patients with primary biliary cirrhosis.
- To assess the impact of cyclosporin A on survival, transplantation rates, disease progression, and symptoms.
Main Methods:
- A European multicentre clinical trial was conducted.
- Patients with primary biliary cirrhosis received cyclosporin A.
- Outcomes including survival, need for transplantation, liver histology, and serum bilirubin levels were monitored.
Main Results:
- Cyclosporin A demonstrated a significant delay in death or liver transplantation.
- A reduction in liver-related deaths was observed.
- The rise in serum bilirubin was slowed, and drug toxicity (nephrotoxicity, hypertension) was low at studied doses.
Conclusions:
- Cyclosporin A is a promising immunomodulatory treatment for primary biliary cirrhosis.
- The drug offers potential benefits in prolonging survival and slowing disease progression.
- Cyclosporin A exhibits a favorable safety profile in the context of PBC treatment.